FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Omeros Corporation (NASDAQ: OMER) | Delayed: 16.57 -0.29 (1.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.86 | 52 Week High | $16.80 | |||
| Open | $16.80 | 52 Week Low | $7.20 | |||
| Day High | $16.80 | P/E | N/A | |||
| Day Low | $16.37 | EPS | $-1.64 | |||
| Volume | 698,891 | |||||
